کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4001592 | 1259415 | 2008 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
تومور شناسی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma](/preview/png/4001592.png)
چکیده انگلیسی
Vascular endothelial growth factor (VEGF) pathway activation leads to the angiogenic phenotype of renal cell carcinoma (RCC). Several different strategies targeting various aspects of this pathway have emerged as standard therapy in metastatic RCC. Bevacizumab, a VEGF ligand-binding antibody, sunitinib and sorafenib, small molecule inhibitors of the VEGF receptor, as well as temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR) have all shown substantial clinical activity in metastatic RCC. Several relevant clinical aspects have also emerged with use of these agents such as defining resistance, measurement of response, and combination therapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 26, Issue 5, September–October 2008, Pages 543–549
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 26, Issue 5, September–October 2008, Pages 543–549
نویسندگان
Brian I. Rini, Keith Flaherty,